GENEVA, April 28, 2008 (AFP) - Two major organisations for access to AIDS medication on Monday announced new deals with generic medicine manufacturers to reduce the price of second-line anti-retroviral drugs.
Six new and more affordable child-friendly formulations would also be made available under the new agreements, said the two organisations, UNITAID and the Clinton Foundation HIV/AIDs Initiative.
Compared to prices they announced in May last year, the reduction would be as much as 19 percent for the most frequently used second-line treatment such as tenofovir, lamivudine and lopinavir/ritonavir.
The latest prices for a second-line regimen involving all three drugs are 16 percent lower than the average price in low-income countries and 46 percent lower than in middle-income countries.
Second-line treatments are necessary for patients who have developed a resistance to first-line treatments.
They currently cost 5-10 times more than a first-line therapy in a low-income country, thereby limiting access for many patients in these countries.
Almost 500,000 patients will need such medication by 2010, according to the two organisations.
UNITAID, a UN-backed drugs funding initiative, also announced the extension of its pediatric project, with six new formulations which are more child-friendly.
"Today's announcement is an important step in helping to save the millions of children and adults infected with HIV in the developing world who still lack access to life-saving drugs," said former United States President Bill Clinton, who launched the foundation.
UNITAID's Executive Board chairman Philippe Douste-Blazy added: "This achievement represents a major step in our partnership to provide more treatments to hundreds of thousands of children through 2010 and to continue to lower the price of second-line treatment."
080428
AF080420
Copyright ©AFP 2008. All Rights Reserved. AFP articles contained on the AEGiS web site may not be reproduced, distributed, transmitted, displayed, published or broadcast without AFP's prior written permission. You may make one copy of each article for your personal, non-commercial use only; more copies would require AFP's prior written permission obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP photos or materials. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP stories, photos or graphics. http://www.afp.com/
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.